Clinical Trial Update: Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder [Phase 3]

View source ↗

Summary

Phase 3 trial update showing long-term safety and efficacy of the beta-3 agonist mirabegron (YM178) for overactive bladder; results completed and posted in 2012…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED | Results posted: 2012-10-19